OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
Business Wire•22/10/2026•13:08 ET
5
Key Highlights
- ➤Operating result -€2.17M, improving 32% excluding 2025’s €13M inventory gain
- ➤Net loss -€2.04M, improving 35% on an adjusted year-over-year basis
- ➤Cash position €2.86M as of June 30, 2026, including MJFF funding
- ➤MJFF funding supports OPM-201’s planned Phase 1b Parkinson’s trial in 2027
- ➤Going-concern status depends on securing additional financial resources
- ➤OPM-101 REVERT Phase 1b/2a melanoma trial preparations continued
Expert Statements
Philippe Genne, Chairman and CEO of Oncodesign Precision Medicine
“OPM continues to move towards its therapeutic objective, with two active compounds reaching the clinical proof-of-concept stage in oncology and Parkinson’s disease. There are currently no therapeutic solutions for these conditions, and our role is to successfully overcome this challenge. We can only overcome it if we secure the financial resources required to achieve this goal.”
Karine Lignel, Deputy CEO and COO of Oncodesign Precision Medicine
“Our half-year financial results highlight our meticulous cost management and our constant pursuit of cost savings, while moving forward with our priority programs as far as possible. The support from the Michael J. Fox Foundation has been essential and enables us to continue developing OPM-201, while we have completed preparations for the clinical trial of OPM-101 in immuno-oncology. We are continuing to seek partners to license or sell either of our assets.”
OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
* OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease
Get started
Create a free account to read the full story.